Effect of Cabergoline on biochemical and anthropometric parameters of patient with Impaired Glucose metabolism (Impaired Fasting Glucose/Impaired Glucose Tolerance)

INTERVENTION: addition of Cabergoline 0.5 mg oral tabletes twice weekly for 4 month or placebo in patients with prediabetes receiving a balanced diet, to to measure patient compliance to Cabergoline, tablet returned counted at the final visit, in addition to comparing thr prolactin level of every patient. CONDITION: Prediabetes PRIMARY OUTCOME: Improving Insulin secretion based on HOMA‐Beta model. ; HOMA‐Beta will be calculated as HOMA‐IR. reversal of insulin resistance based on HOMA‐IR Model. ; HOMA‐IR will be calculated, using a fasting plasma sample, insulin level, and was derived by use of the insulin‐glucose product, divided by a constant (405 when using mg/dL and 22.5 when using mmol/L for FPG reporting) SECONDARY OUTCOME: alleviation of HbA1C level ; HbA1C measured using enzymatic method and high‐performance liquid chromatography (HPLC) INCLUSION CRITERIA: Fasting Plasma Glucose (FPG): 100‐110 mg/dL or/and 2 hour Plasma Glucose after Oral Glucose Tolerance Test (2hPG): 140‐199 mg/dL.